TD Cowen raised the firm’s price target on GeneDx (WGS) to $118 from $75 and keeps a Buy rating on the shares. The firm reviewed its financial model following the stock’s rise and believes there is room for upside noting its published trial studies support its strong competitive position.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS: